PharmaCyte Biotech, Inc.
PMCB
$0.94
$0.044.34%
NASDAQ
| 10/31/2025 | 07/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 63.99% | -17.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 62.22% | -18.58% | |||
| Operating Income | -62.22% | 18.58% | |||
| Income Before Tax | 11.27% | -171.15% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.27% | -171.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.27% | -171.15% | |||
| EBIT | -62.22% | 18.58% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -0.67% | -177.75% | |||
| Normalized Basic EPS | -30.61% | -417.88% | |||
| EPS Diluted | -0.67% | -177.75% | |||
| Normalized Diluted EPS | -30.61% | -417.88% | |||
| Average Basic Shares Outstanding | 0.00% | -0.86% | |||
| Average Diluted Shares Outstanding | 0.00% | -0.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||